Fluorine-18-Fluoroethylcholine PET/CT in the detection of prostate cancer: A South African experience - Abstract

OBJECTIVE: Imaging with fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) has, until recently provided disappointing results with low sensitivity ranging from 31%-64% in patients with well-differentiated prostate cancer (PC) at all prostatic specific antigen (PSA) levels while fluorine-18-fluoroethylcholine (18F-FECh) PET/CT showed about 85% sensitivity in restaging patients after relapse.

We present our experience of the sensitivity of 18F-FECh PET/CT in the early stages of PC.

SUBJECT AND METHODS: Fifty patients were prospectively recruited and imaged, of which 40 fulfilled all inclusion criteria. Our patients had an average age of 65.5 years. Fifteen patients were referred for initial staging, with the remaining 25 referred for restaging and all patients had histologically confirmed adenocarcinoma. Patients were imaged by 18F-FECh PET/CT. Findings were evaluated qualitatively and quantitatively and compared to the results of histology, PSA, Gleason score and bone scintigraphy. The prostate SUVmax was also used.

RESULTS: Thirty-one patients demonstrated abnormal pelvic- and or extra- pelvic findings on 18F-FECh PET/CT, which was consistent with malignant or metastatic involvement. The prostate SUVmax could not be used to predict the presence or absence of metastatic disease.

CONCLUSION: Findings of this paper suggest that 18F-FECh PET/CT in 30/40 cases (estimated as 75%) was helpful in the initial staging, restaging and lymph node detection of patients with PC. The SUVmax was not helpful. We diagnosed more PC cases in our African-American patients as compared to the Caucasian patients.

Written by:
Vorster M, Modiselle M, Ebenhan T, Wagener C, Sello T, Zeevaart JR, Moshokwa E, Sathekge MM.   Are you the author?
University of Pretoria and Steve Biko Academic Hospital Private Bag X169, Pretoria, 0001, South Africa.  

Reference: Hell J Nucl Med. 2015 Jan-Apr;18(1):53-9.

PubMed Abstract
PMID: 25840573

UroToday.com Prostate Cancer Section